The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Fractyl Health (Nasdaq:GUTS) is cutting nearly a fifth of its workforce as it streamlines resources and shifts focus toward ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced ...

Nuvation Bio Inc. , a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

Therapy has long been about the delicate dance of self-understanding—therapists attuning to the unsaid, guiding clients ...

After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...

Today's medical AI systems represent not just a new diagnostic tool, but a new kind of medical reasoning altogether, writes ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 14.16%, which has investors questioning if this is right time to sell.

H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.